FDA Issues Complete Response Letter for Zynquista (sotagliflozin)

PARIS and THE WOODLANDS, TX–  March 22, 2019 -  The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for investigational Zynquista (sotagliflozin)*, a dual SGLT1 and...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news